[including dactylitis, enthesitis] or function-limiting inflammatory disease at few sites), and rapidly progressive disease. Â¶ Because there are currently no widely agreed-upon definitions of disease severity, psoriasis severity should be established by the health care provider and patient on a case-by-case basis. In clinical trials, severe psoriasis has been defined as a Psoriasis Area and Severity Index (PASI) score ( 25 have no contraindications to high-impact exercises ( DISCUSSION We present herein the first ACR/NPF guideline for the treatment of psoriatic arthritis. The goal of this guideline is to assist health care providers in managing active PsA in their patients, including optimizing therapy. PsA is a heterogene-ous and multifaceted inflammatory disease, and its different clinical features (e.g., peripheral arthritis, psoriasis, nail disease, enthesitis, dactylitis, axial disease) sometimes respond differently to therapy. Despite an expansion in the number of new therapies